

R³ is selected from the group consisting of: hydrogen and C₁₋₄alkyl, optionally substituted with 1-3 hydroxy or halo groups;

each R⁴ is independently selected from the group consisting of: hydroxy, halo, -CO₂H, C₁₋₄alkyl, -S(O)_kC₁₋₃alkyl, wherein k is 0, 1 or 2, C₁₋₃alkoxy, C₃₋₆ cycloalkoxy, aryl and aralkoxy, the alkyl portions of said C₁₋₄alkyl, -S(O)_kC₁₋₃alkyl, C₁₋₃alkoxy and C₃₋₆ cycloalkoxy optionally substituted with 1-3 halo groups;


C is selected from the group consisting of:

- (1) ~~C₁₋₈alkyl, C₁₋₈alkoxy, (C=O)C₁₋₆alkyl or CHOH-C₁₋₆alkyl, said C₁₋₈alkyl, C₁₋₈alkoxy, (C=O)C₁₋₆alkyl and CHOH-C₁₋₆alkyl optionally substituted with phenyl, and~~
- (2) ~~phenyl or HET, wherein HET is thienyl each optionally substituted with 1-3 substituents independently selected from the group consisting of: halo, phenyl, C₁₋₄alkyl and C₁₋₄alkoxy, said C₁₋₄alkyl and C₁₋₄alkoxy groups optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from halo and hydroxyl, and said phenyl optionally substituted with 1 to 5 groups independently selected from the group consisting of: halo and C₁₋₄alkyl, optionally substituted with 1-3 halo groups,~~

or C is not present;

~~when C is not present then B is selected from the group consisting of: phenyl, C₅₋₁₆alkyl, C₅₋₁₆alkenyl, C₅₋₁₆alkynyl, CHOH-C₄₋₁₅alkyl, CHOH-C₄₋₁₅alkenyl, CHOH-C₄₋₁₅alkynyl, C₄₋₁₅alkoxy, O-C₄₋₁₅alkenyl, O-C₄₋₁₅alkynyl, C₄₋₁₅alkylthio, S-C₄₋₁₅alkenyl, S-C₄₋₁₅alkynyl, CH₂-C₃₋₁₄alkoxy, CH₂-O-C₃₋₁₄alkenyl, CH₂-O-C₃₋₁₄alkynyl, (C=O)-C₄₋₁₅alkyl, (C=O)-C₄₋₁₅alkenyl, (C=O)-C₄₋₁₅alkynyl, (C=O)-O-C₃₋₁₄alkyl, (C=O)-O-C₃₋₁₄alkenyl, (C=O)-O-C₃₋₁₄alkynyl, (C=O)-N(R⁶)(R⁷)-C₃₋₁₄alkyl, (C=O)-N(R⁶)(R⁷)-C₃₋₁₄alkenyl, (C=O)-N(R⁶)(R⁷)-C₃₋₁₄alkynyl, N(R⁶)(R⁷)-(C=O)-C₃₋₁₄alkyl, N(R⁶)(R⁷)-(C=O)-C₃₋₁₄alkenyl and N(R⁶)(R⁷)-(C=O)-C₃₋₁₄alkynyl,~~

when C is phenyl or HET then B is selected from the group consisting of: C₁₋₆alkyl, C₁₋₅alkoxy, -(C=O)-C₁₋₅alkyl, -(C=O)-O-C₁₋₄alkyl, -(C=O)-N(R⁶)(R⁷)-C₁₋₄alkyl, C₁₋₃alkyl



, phenyl and HET, and

when C is C₁₋₈alkyl, C₁₋₈alkoxy, -(C=O)-C₁₋₆alkyl or -CHOH-C₁₋₆alkyl then B is phenyl; and

R⁶ and R⁷ are independently selected from the group consisting of: hydrogen, C₁₋₉alkyl and -(CH₂)_p-phenyl, wherein p is 1 to 5 and phenyl is optionally substituted with 1-3 substituents independently selected from the group consisting of: C₁₋₃alkyl and C₁₋₃alkoxy, each optionally substituted with 1-3 halo groups.

2. (canceled)

3. (original) The compound according to Claim 1 wherein n is 2.

4. (original) The compound according to Claim 1 wherein n is 3.

5. (original) The compound according to Claim 3 wherein each R¹ and R² is independently selected from the group consisting of: hydrogen, -CO₂H, hydroxy, halo, C₁₋₃alkyl and phenyl.


6 to 10. (canceled)

11. (original) The compound according to Claim 1 wherein R³ is hydrogen or methyl.


12. (original) The compound according to Claim 1 wherein each R⁴ is independently selected from the group consisting of: halo, hydroxy, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, phenyl, benzyloxy and cyclopropyloxy.

13 to 17. (canceled)

18. (original) The compound according to Claim 1 wherein **B-C** is




or



19. (original) The compound according to Claim 1 wherein Ar is phenyl and the group **-B-C** is attached to the phenyl ring at the 3- or 4-position.

20. (currently amended) A compound of Formula II



II

or a pharmaceutically acceptable salt or hydrate thereof, wherein

the group **-B-C** is attached to the phenyl ring at the 3- or 4-position;

n is 2, 3 or 4;

each R¹ and R² is independently selected from the group consisting of: hydrogen, -CO₂H, hydroxy, halo, C₁₋₃alkyl and phenyl, said C₁₋₃alkyl and phenyl optionally substituted with 1-3 halo group;

~~A is selected from the group consisting of: 1H-tetrazol-5-yl, PO₂H₂, PO₃H₂, -CO₂H and PO(R⁵)OH, wherein R⁵ is selected from the group consisting of: C₁₋₄alkyl, hydroxyC₁₋₄alkyl, C(O)-C₁₋₂alkoxy and benzyl, wherein both the methyl and phenyl portions of said benzyl are optionally substituted with 1-3 halo or hydroxyl groups;~~

R³ is hydrogen or methyl;

each R⁴ is independently selected from the group consisting of: halo, hydroxy, C₁₋₃alkyl, C₁₋₃alkoxy, C₁₋₃alkylthio, phenyl, benzyloxy and cyclopropyloxy; and


~~B-C is selected from the group consisting of:~~

- ~~—— (1) — B is C₈₋₁₀alkyl and C is not present.~~
- ~~—— (2) — B is C₄₋₁₁alkoxy and C is not present.~~
- ~~—— (3) — B is phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of: halo, C₁₋₄alkyl and C₁₋₄alkoxy, and C is selected from the group consisting of: hydrogen, phenyl, C₁₋₈alkyl, C₁₋₈alkoxy, (C=O)-C₁₋₆alkyl and -CHOH-C₁₋₆alkyl, said C₁₋₈alkyl, C₁₋₈alkoxy, (C=O)-C₁₋₆alkyl and -CHOH-C₁₋₆alkyl optionally substituted with phenyl;~~


~~(4) B is CHOH-C₆₋₁₀alkyl, C₆₋₁₀alkylthio, CH₂-C₅₋₉alkoxy, (C=O)-C₆₋₁₀alkyl, (C=O)-O-C₅₋₉alkyl, (C=O)-N(R⁶)(R⁷)-C₅₋₉alkyl or N(R⁶)(R⁷)-(C=O)-C₅₋₉alkyl, and C is not present.~~

~~(5) B is C₁₋₆alkyl or C₁₋₅alkoxy and C is phenyl.~~


~~(6) B-C is~~



or





21. (currently amended) A compound selected from the group consisting of:








Serial No.: 10/500,811
Case No.: 21020P
Page 8













































Page 22























or a pharmaceutically acceptable salt of any of the foregoing compounds.

22. (withdrawn) A method of treating an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient a compound in accordance with Claim 1 in an amount that is effective for treating said immunoregulatory abnormality.

23 to 33. (canceled)

34. (withdrawn) A method of suppressing the immune system in a mammalian patient in need of immunosuppression comprising administering to said patient an immunosuppressing effective amount of a compound of Claim 1.

35. (canceled)